Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report

Although there has been significant progress in immune-checkpoint inhibitor (ICI) treatment, it remains controversial whether they should be used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). We herein report the case of an NSCLC patient with...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Yuri, Yamamoto, Momoko, Ikushima, Hiroaki, Ohara, Sayaka, Takeshima, Hideyuki, Sakatani, Toshio, Usui, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696780/
https://www.ncbi.nlm.nih.gov/pubmed/31427953
http://dx.doi.org/10.1159/000501848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696780/
https://www.ncbi.nlm.nih.gov/pubmed/31427953
http://dx.doi.org/10.1159/000501848

Ejemplares similares